Technical Analysis for DOVA - Dova Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
DOVA closed down 4.19 percent on Monday, October 15, 2018, on 72 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical DOVA trend table...|
|Date||Alert Name||Type||% Chg|
|Oct 15||New 52 Week Closing Low||Bearish||0.00%|
|Oct 15||New 52 Week Low||Weakness||0.00%|
|Oct 15||Multiple of Ten Bearish||Other||0.00%|
|Oct 15||Wide Bands||Range Expansion||0.00%|
|Oct 15||Oversold Stochastic||Weakness||0.00%|
|Oct 12||Multiple of Ten Bullish||Other||-4.19%|
|Oct 12||Wide Bands||Range Expansion||-4.19%|
|Oct 12||Oversold Stochastic||Weakness||-4.19%|
|Oct 11||New 52 Week Closing Low||Bearish||-2.02%|
|Oct 11||Multiple of Ten Bearish||Other||-2.02%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Dova Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD). The Company’s product candidate, avatrombopag is an orally administered thrombopoietin receptor agonist, or TPO-RA. The Company has completed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with CLD. The Company has not generated any revenue.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more DOVA news...
|52 Week High||37.0|
|52 Week Low||19.25|
|200-Day Moving Average||26.6054|
|50-Day Moving Average||22.8584|
|20-Day Moving Average||21.6595|
|10-Day Moving Average||20.231|
|Average True Range||1.1097|
|Chandelier Exit (Long, 3 ATRs )||21.7609|
|Chandelier Exit (Short, 3 ATRs )||22.5791|
|Upper Bollinger Band||25.2206|
|Lower Bollinger Band||18.0984|
|Percent B (%b)||0.19|
|MACD Signal Line||-0.9168|
|Market Cap||498.16 Million|
|Num Shares||25.7 Million|
|Price-to-Earnings (P/E) Ratio||-9.29|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||21.21|
|Resistance 3 (R3)||21.35||20.89||20.91|
|Resistance 2 (R2)||20.89||20.44||20.82||20.81|
|Resistance 1 (R1)||20.16||20.16||19.93||20.02||20.71|
|Support 1 (S1)||18.97||19.25||18.74||18.83||18.13|
|Support 2 (S2)||18.51||18.97||18.44||18.03|
|Support 3 (S3)||17.78||18.51||17.93|
|Support 4 (S4)||17.64|